New 20-year data show a survival rate of 90% with few repeat surgeries after this complex operation that can only be ...

Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests ...

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...

Our Bureau, Mumbai Thursday, January 30, 2025, 15:15 Hrs [IST] ...

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

Middle-aged adults who need an aortic valve replacement fare better with mechanical devices than with the valves made from ...

A study reveals that middle-aged adults fare better with mechanical aortic valves compared to animal tissue-based valves. The research, presented at the Society for Thoracic Surgery annual meeting, ...

Australia’s Therapeutic Goods Administration posted a draft guidance dealing with non-mandatory audits for premarket applications, which says that a transcatheter aortic valve replacement device that ...

These latest data reinforce years of smaller studies, but whether they should change practice is a matter of debate.

Young patients who have undergone the Ross procedure for aortic valve disease have shown excellent long-term survival, the ...

Annual Meeting reveals that mechanical aortic valve replacements (AVRs) provide significant long-term survival benefits for ...